Oxford Asset Management’s Cytokinetics CYTK Stock Holding History

Oxford Asset Management’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$242K	Buy	+2,836	New	+$204K	0.12%	264
2019 Q4	–	Sell	-156,783	Closed	-$1.78M	–	1801
2019 Q3	$1.78M	Sell	156,783 -61,991	-28%	-$778K	0.04%	615
2019 Q2	$2.46M	Buy	218,774 +22,656	+12%	+$218K	0.05%	556
2019 Q1	$1.59M	Buy	196,118 +95,337	+95%	+$701K	0.03%	695
2018 Q4	$637K	Buy	+100,781	New	+$739K	0.02%	1088
2017 Q3	–	Sell	-134,002	Closed	-$1.62M	–	1559
2017 Q2	$1.62M	Sell	134,002 -59,866	-31%	-$832K	0.03%	706
2017 Q1	$2.49M	Buy	+193,868	New	+$2.27M	0.06%	367
2016 Q1	–	Sell	-147,812	Closed	-$1.55M	–	821
2015 Q4	$1.55M	Sell	147,812 -254,296	-63%	-$2.49M	0.04%	443
2015 Q3	$2.69M	Buy	402,108 +209,421	+109%	+$1.43M	0.08%	244
2015 Q2	$1.29M	Buy	192,687 +57,975	+43%	+$380K	0.04%	415
2015 Q1	$913K	Buy	134,712 +36,632	+37%	+$274K	0.02%	475
2014 Q4	$722K	Buy	+98,080	New	+$421K	0.02%	520
2014 Q2	–	Sell	-98,132	Closed	-$932K	–	714
2014 Q1	$932K	Buy	+98,132	New	+$888K	0.03%	462

Other funds holding CYTK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Oxford Asset Management's CYTK Position: Q2 2026 in Review

Oxford Asset Management opened a new position in Cytokinetics (CYTK) in Q2 2026: 2,836 shares worth $242K. The stake represents 0.12% of the portfolio and ranks #264 among its holdings. This is a return to the name: Oxford Asset Management previously reported a position in CYTK as recently as Q3 2019.

Oxford Asset Management first reported a position in CYTK in Q1 2014 and has held it in 13 quarters since. The position peaked at $2.69M in Q3 2015. 483 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

Oxford Asset Management held 2,836 shares of Cytokinetics worth $242K as of Q2 2026.
Cytokinetics was a new Oxford Asset Management position in Q2 2026.
Cytokinetics made up 0.12% of Oxford Asset Management's portfolio in Q2 2026, its #264 holding.
Oxford Asset Management first reported a position in Cytokinetics in Q1 2014 and has held it in 13 quarters since.
Oxford Asset Management's Cytokinetics position peaked at $2.69M in Q3 2015.
483 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Oxford Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.